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A B S T R A C T
Stroke is the second leading cause of death globally and represents a major cause of devastating long-term disability. Despite sustained efforts to develop clinically effective neuroprotective therapies, presently there is no clinically available neuroprotective agent for stroke. As a central mediator of neurodamaging events in stroke, mitochondria are recognised as a critical neuroprotective target, and as such, provide a focus for developing mitochondrial-targeted therapeutics. In recent years, cationic arginine-rich peptides (CARPs) have been identified as a novel class of neuroprotective agent with several demonstrated mechanisms of action, including their ability to target mitochondria and exert positive effects on the organelle. This review provides an overview on neuronal mitochondrial dysfunction in ischaemic stroke pathophysiology and highlights the potential beneficial effects of CARPs on mitochondria in the ischaemic brain following stroke.
Stroke background: epidemiological 'Snapshot' and need for neuroprotection
Acute stroke is a global epidemic responsible for the second and third leading causes of death and disability respectively (Kassebaum et al., 2016; Lozano et al., 2012) . In 2010, the global prevalence of stroke was estimated to be approximately 33 million, with 16.9 million individuals experiencing their first stroke (Mozaffarian et al., 2015) . A significant proportion of stroke survivors are left with cognitive and physical disabilities (Douiri et al., 2013; Sun et al., 2014) , or impaired language and verbal communication (Tatemichi et al., 1994) . The burden of stroke to the global community is continuing to increase due to the aging world population and the increasing prevalence of risk factors for stroke, such as hypertension (Beckett et al., 2008) , diabetes (Khoury et al., 2013) , hyperlipidaemia (Zavoreo et al., 2012) , heart disease (Vasan et al., 2002) , obesity (Suk et al., 2003) and reduced physical activity (Diep et al., 2010; Kelly-Hayes, 2010; McGinn et al., 2008) . As an increasing risk factor, the aging world population is a major concern (Khare, 2016) , with approximately 900 million people aged over 60, rising to an expected 1.5 billion by the year 2050 (World Health Organization et al., 2011) . To make matters worse, there are currently no clinically available neuroprotective agents for the acute treatment of stroke to minimise brain injury, and current therapies are mainly restricted to endovascular recanalisation interventions for a selected subgroup of ischaemic stroke patients. However, most patients are ineligible for such interventions due to narrow therapeutic time windows (e.g. 4.5 h for tPA thrombolysis) and/or the need for specialised tertiary hospital facilities to perform the procedure (e.g. mechanical thrombectomy). Notwithstanding, the recent DAWN and DE-FUSE 3 clinical trials demonstrated that thrombectomy, when performed up to 16 to 24 h post-stroke symptoms, could improve outcomes in a subgroup of patients selected on the basis of the presence of potentially salvageable penumbral tissue (Albers et al., 2018; Nogueira et al., 2017) . For this reason it is now recommended that a "tissue window" rather than a "time window" be used when considering therapeutic interventions, such as thrombectomy and neuroprotection. Furthermore, it highlights the need for a safe neuroprotective agent that can be administered early after stroke onset to slow brain infarction and https://doi.org/10.1016/j.nbd.2018.09.010 Received 14 May 2018; Received in revised form 26 August 2018; Accepted 11 September 2018
